BioSpace News Archive

Drug Development

Zero to Hero – Tainted Company Bounces Back with Successful COVID-19 Drug

Humanigen, the biotech briefly run by “Pharma Bro” Martin Shkreli under the name KaloBios up until his arrest, is back in the game with an antibody that is keeping COVID-19 patients off of ventilators and improving survival.

March 29, 2021
·
2 min read
·
Kate Goodwin
Business

Caribou Biosciences is Armoring Cells to Fight Disease Through CRISPR

The company’s overarching aim is to edit and equip cells with molecular tools, through CRISPR, to eliminate certain cancers.

March 29, 2021
·
6 min read
·
Maggie Chen
uniQure Investigation Clears Hemophilia B Gene Therapy of Causing Liver Cancer

An investigation was conducted by an independent laboratory and reviewed by leading external experts in the field.

March 29, 2021
·
2 min read
·
Mark Terry
FDA

After Many Delays, BMS and bluebird Win Approval for Multiple Myeloma CAR-T, Abecma

The FDA-approved ide-cel, which will be marketed under the brand name Abecma is going to be the second therapy for myeloma. Here’s everything you need to know.

March 29, 2021
·
3 min read
·
Alex Keown
Drug Development

Orphazyme Drug Misses Both Endpoints in Rare Muscle-Wasting Disease Trial

Orphazyme announced its Phase II/III clinical trial of arimoclomal for inclusion body myositis (IBM) failed to hit both its primary and secondary endpoints.

March 29, 2021
·
2 min read
·
Mark Terry
Policy

WHO Report on COVID-19 Origin Focuses on Spread from Wild Animals

The report listed four scenarios in order of likelihood, with the top being from bats through another animal.

March 29, 2021
·
4 min read
·
Mark Terry
Drug Development

NeuroRx Reports Positive RLF-100 Data for Critically Ill COVID-19 Patients

A new readout from a Phase IIb/III trial showed intravenous RLF-100 (aviptadil) met the primary endpoint of improving survival and recovery at 60 days post-treatment for respiratory failure in critically ill patients with COVID-19.

March 29, 2021
·
2 min read
·
Mark Zipkin
Policy

French Court Fines Servier for Damages Caused by Weight-Loss Drug Mediator

Servier was found guilty of manslaughter and deceptive marketing practice for its Mediator drug for weight loss. The Paris-based company was fined $3.12 million.

March 29, 2021
·
2 min read
·
Alex Keown
Retinal Drugs and Biologics Market: Increasing incidence of retinal disorder to drive the market

Human eyes are highly delicate and can be affected with the minutest of the things. Therefore, it security is of high importance.

March 29, 2021
·
4 min read
Fibromyalgia Market - North America Continues to Dominate the Market | TMR Research Study

Fibromyalgia also called Fibrositis, is a chronic pain disorder causing a widespread pain and tenderness to touch. Fibromyalgia affects people physically, mentally and socially.

March 29, 2021
·
7 min read